United States· US:61755-008_541a4e20-6a70-4164-8504-413f0d654042
LIBTAYO
A cemiplimab product containing cemiplimab, registered in United States by Regeneron Pharmaceuticals, Inc.. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Cemiplimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF06 (cemiplimab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Cemiplimab · ATC L01FF06
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CEMIPLIMAB
- Manufacturer
- Regeneron Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L01FF06
- ATC class
- Cemiplimab
- Defined daily dose
- 16.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 6, 2026
Packs & prices · 2
- ndc1161755008011 VIAL, SINGLE-USE in 1 CARTON (61755-008-01) / 7 mL in 1 VIAL, SINGLE-USE
- ndc1161755-008-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
17 interactions on record for cemiplimab.
Graded by severity as the source publishes them — 17 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cemiplimab · interactions on record
17 records
- 17 moderate
Most severe, free to view
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- BetamethasoneA07EA04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cemiplimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainLIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- FinlandLIBTAYORegeneron Ireland Designated Activity Company (DAC)
- NorwayLibtayoAbacus Medicine A/S
- CzechiaLIBTAYORegeneron Ireland Designated Activity Company, Dublin
- FranceLIBTAYO 350 mg, solution à diluer pour perfusionREGENERON IRELAND DESIGNATED ACTIVITY COMPANY (IRLANDE)
- United KingdomLibtayo 350mg/7ml concentrate for solution for infusion vialsRegeneron UK Ltd
- IrelandLIBTAYO 350 mg Concentrate for solution for infusionRegeneron Ireland U.C.
- IcelandLibtayoRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Libtayo
- Liechtenstein · Libtayo
- Norway · Libtayo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b4282e75-f015-4fb8-a465-e4312d57cb82 GET /v1/drugs/b4282e75-f015-4fb8-a465-e4312d57cb82?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "50",
"substance": "CEMIPLIMAB",
"productndc": "61755-008",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761097",
"marketing_category": "BLA"
}See everything about cemiplimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.